Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

Semaglutide 5 mg

$129Per Unit

Analytical-grade glucagon-like peptide-1 analog synthesized to ≥99.4% purity. Shipped in sterile lyophilized form with complete lot analysis documentation.

Lot SMG2026-02B · COA on request
Lyophilized peptide, sterile stoppered vial, 5 mg fill
2–8°C (stable 30 days)

5 × $129.00 = $645.00 $419.25 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

Semaglutide 5 mg

$419.25 for 5 · 35% off

Research use only
Semaglutide 5 mg research packaging
Lyophilized peptide, sterile stoppered vial, 5 mg fill
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot SMG2026-02B) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

Semaglutide

Regulatory status
FDA-approved medicine: Ozempic (type 2 diabetes, Dec 2017) and Wegovy (chronic weight management, Jun 2021).
Strongest evidence
Approved drug backed by large phase 3 and outcome trials
Overview

Semaglutide is a long-acting GLP-1 receptor agonist made by Novo Nordisk, sold as Ozempic, Wegovy and the oral Rybelsus.

What researchers study it for
  • Type 2 diabetes
  • Obesity and overweight
  • Cardiovascular risk in people with obesity
Mechanism

Activates the GLP-1 receptor: glucose-dependent insulin release, slower gastric emptying and reduced appetite.

Evidence (3)
  1. Human · randomized trial

    STEP 1 (phase 3, NEJM 2021)

    1,961 adults with obesity or overweight without diabetes, 68 weeks. Mean weight change −14.9% versus −2.4% with placebo; nausea and diarrhoea were the most common adverse events.[1]

  2. Human · randomized trial

    SELECT (cardiovascular outcomes, NEJM 2023)

    17,604 people with cardiovascular disease and overweight or obesity but no diabetes. Major cardiovascular events occurred in 6.5% with semaglutide versus 8.0% with placebo (hazard ratio 0.80); stopping because of adverse events was more common with semaglutide (16.6% vs 8.2%).[2]

  3. Approved drug

    FDA approvals

    Ozempic approved Dec 5, 2017; Wegovy approved Jun 4, 2021 (Drugs@FDA).[3][4]

Limitations of the evidence
  • Results describe the approved medicines in the populations studied.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (4)
  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)Wilding JPH et al. N Engl J Med. 2021 Human · randomized trial
  2. 2.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)Lincoff AM et al. N Engl J Med. 2023 Human · randomized trial
  3. 3.Ozempic (semaglutide) - original approval 2017-12-05Drugs@FDA, NDA 209637 Approved drug
  4. 4.Wegovy (semaglutide) - original approval 2021-06-04Drugs@FDA, NDA 215256 Approved drug
Every published studyPubMed search: Semaglutide(opens in a new tab)Every registered trialClinicalTrials.gov search: Semaglutide(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.